Physician profile
Michael S Gelfand
NPI 1982662961
$486,086.40
in general payments reported to CMS, 2019-2025
12 companies · $24K in 2025
The $24K reported for 2025 was more than what 96% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $194K · 2020: $59K · 2021: $75K · 2022: $57K · 2023: $31K · 2024: $45K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $49K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $39K · Travel and Lodging: $5,425 · Consulting Fee: $4,000 · Food and Beverage: $2,910 · Education: $25.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $48,672.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $39,491.00 |
| Travel and Lodging | $5,425.17 |
| Consulting Fee | $4,000.00 |
| Food and Beverage | $2,909.69 |
| Education | $25.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $159,989.75 | 2019-2021 | |
| La Jolla Pharmaceutical Company | $152,787.06 | 2020-2025 | Xerava, Xacduro, Zevtera |
| Abbvie INC. | $70,497.51 | 2021-2025 | |
| Tetraphase Pharmaceuticals, INC. | $46,435.44 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $39,682.22 | 2019-2025 | Zerbaxa, Prevymis, Dificid |
| Cumberland Pharmaceuticals, INC. | $7,732.58 | 2019-2020 | |
| Melinta Therapeutics, LLC | $4,661.34 | 2019 | |
| Diasorin INC. | $4,000.00 | 2024 | |
| Paratek Pharmaceuticals, INC. | $124.98 | 2024 | Nuzyra |
| Astellas Pharma US INC | $104.73 | 2019-2023 | Cresemba |
| Shionogi INC | $54.55 | 2024 | Fetroja |
| Insmed, INC. | $16.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gelfand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.